Antifungal Susceptibility Patterns of Thermotolerant Non-Albicans Candida Isolates from Diabetes Mellitus and Malignancy Patients in Plateau State, Nigeria

Abdel-Hamid, D., El-Sayed, R., & Hassan, H. (2023). Prevalence and antifungal resistance of non- albicans Candida species among immunocompromised patients. Journal of Mycology and Infectious Diseases, 12(3), 45–52. Akinbobolaid, O., Okoro, E., & Musa, H. (2023). Thermotolerant non-albicans Candida The study focusses on the relationship between thermotolerantial resistance in sub-Saharan Africa. African Journal of Clinical Microbiology, 10(4), 121–133. Awada, A., Bacha, U., & Martinez, F. (2024). Mechanisms of azole resistance in Candida species: ERG11 mutations and efflux pump overexpression. Frontiers in Fungal Biology, 5, 123– 136. Azar, M., Scully, B., & Kollee, L. (2017). Effect of immunosuppressive therapy on fungal colonisation and infection. Clinical Immunology Reviews, 8(2), 89–102. Bhattacharya, S., Chakrabarti, A., & Pasqualotto, A. C. (2020). Epidemiology and clinical spectrum of candidiasis. Mycoses, 63(5), 453–466. Bhandari, V., Savio, J. C., & Giri, S. (2023). Nosocomial Candida infections: Patterns and clinical outcomes. Journal of Hospital Infection, 125, 15–22. Charvis, T. L., Fernandez, A. G., & Zhou, T. (2025). Amphotericin B resistance in Candida parapsilosis: Biofilm-associated mechanisms. Antimicrobial Agents and Chemotherapy, 69(1), e02047-24. Chowdhary, A., Sharma, C., & Meis, J. F. (2017). Candida auris: A rapidly emerging cause of hospital-associated multidrug-resistant fungal infections globally. PLoS Pathogens, 13(5), e1006290. Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., & Chiller, T. (2015). Changes in incidence and antifungal drug resistance in Candida bloodstream infections—United States, 2008–2013. MMWR Morbidity and Mortality Weekly Report, 64(1), 1–10. Çoban, A. Y., Ertürk, S., & Y?ld?z, A. (2023). Non-albicans Candida species: Clinical significance and resistance profiles. Journal of Infectious Fungal Diseases, 14(2), 78–87. Du, X., Sun, Y., & Li, L. (2020). Distribution of Candida species in clinical samples: An epidemiological survey. Infection and Drug Resistance, 13, 2363–2372. Elkholy, A., Abdelrahman, T., & Youssef, A. (2025). Clinical outcomes and antifungal resThe study focused on the clinicalof C. auris infections. Journal of Clinical Mycology, 17(1), 10–25. Enweani, U. N., Osagie, A., & Iwu, C. (2021). Terbinafine resistance in Candida spp.: A multicentre Nigerian study. West African Journal of Medicine, 40(3), 198–205. Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2022). Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science, 368(6489), 945–950. Hernández-Pabón, D., Rodríguez, A., & Ruiz, M. (2024). Biofilm-mediated antifungal resistance in Candida species: Clinical implications. Journal of Medical Microbiology, 73(2), 115– 124. Heaney, H., Hensgens, M., & Gilbert, D. (2020). Global burden of Candida infections: Epidemiological trends and public health implications. Lancet Infectious Diseases, 20(8), e217–e225. Huang, L., Dong, Q., Zhou, Q., & Chen, W. (2025). Genomic insights into pathogenicity The study provides genomicifungal resistance in Candida species. Journal of Fungal Genomics, 11(1), 3–15. Jones, T. S., Patel, R., & Wang, P. (2024). Clinical significance of thermotolerant non-albicans Candida colonisation. International Journal of Mycology, 9(1), 33–41. Kordalewska, M., & Perlin, D. S. (2019). Identification and molecular characterisation of C. auris. Methods in Molecular Biology, 1918, 17–29. Kühbacher, A., Hoppe, A., & Bargon, J. (2017). Cutaneous candidiasis in immunocomprThe study focused on cutaneoussts. Journal of Dermatological Treatment, 28(6), 500–505. Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chow, N., & Welsh, R. M. (2017). Simultaneous emergence of multidrug-resistant Candida auris on three continents confirmed by whole-genome sequencing and epidemiological analyses. Clinical Infectious Diseases, 64(2), 134–140. Lyman, M., Brown, J., & Miller, A. (2023). Trends in Candida auris incidence in the United States (2019–2023). Emerging Infectious Diseases, 29(7), 1230–1238. Meis, J. F., & Chowdhary, A. (2018). Candida auris: A global fungal public health threat. New England Journal of Medicine, 379(13), 1233–1244. Nnaemeka Emmanuel, O., Olufemi, A. O., & Salami, S. O. (2020). Environmental distribution of Candida species in hospitals in Plateau State. Nigerian Journal of Clinical Microbiology, 15(2), 47–54. Oladele, R. O., Alasoadura, A., & Olorunfemi, A. O. (2022). Absence of C. auris in Nigerian clinical isolates: A whole-genome sequencing study. Mycopathologia, 187(4), 581–590. Otto, L. M., & Babady, N. E. (2023). Clinical characteristics of non-albicans Candida infections in immunocompromised patients. Journal of Clinical Microbiology, 61(9), e01234-23. Osaigbovo, I. O., Etuk, I. U., & Okeke, U. (2027). Azole resistance trends in Nigerian clinical Candida isolates (2018–2026). Antimicrobial Resistance and Infection Control, 16, 58. Parisihni, T., Kumar, R., & Singh, G. (2024). Hyperglycemia and Candida proliferation in diabetic patients. Journal of Diabetes and Its Complications, 38(4), 108–114. Pappas, P. G., Kauffman, C. A., Andes, D., et al. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62, e1–e50. Perfect, J. R. (2017). The antifungal pipeline: A reality check. Nature Reviews Drug Discovery, 16(9), 603–616. Preda, C. D., Georgescu, M., & Pop, R. (2024). Virulence factors in non-albicans Candida species. Acta Microbiologica et Immunologica, 63(1), 11–20. Said, M., Aziz, A., & Abdelrahman, M. (2024). Antifungal resistance patterns amongThe study focusses on the patterns of antifungal resistanceurnal of Medical Mycology, 14(2), 89–98. Schelenz, S., Hagen, F., Rhodes, J. L., et al. (2016). First hospital outbreak of Candida aThis was the firstin Europe. Lancet Infectious Diseases, 16(10), 990–997. Sansom, R. M., Blevins, R. J., & Carter, J. (2024). Transmission dynamics of Candida speThe study focusses on the transmissionthcare environments. Infection Control & Hospital Epidemiology, 45(3), 287–295. Semenya, D., Pule, M., & Tshiamo, W. (2024a). Non-albicans Candida species in diabetic and oncology patients: Clinical prevalence and resistance. African Journal of Laboratory Medicine, 13, 109–117. Semenya, D., Pule, M., & Tshiamo, W. (2024b). Antifungal resistance trends in non-albicans Candida species: A review. Journal of Medical Mycology, 14(3), 112–125. Soriano, S., Guillén, M., & Torres, R. (2023). Antibiotic use and fungal overgrowth: A clinical correlation study. Clinical Therapeutics, 45(2), 240–249. Spiliopoulou, A., Koufaki, M., & Koutsoukou, A. (2022). Biofilm formation by Candida species on medical devices. Journal of Infection Prevention, 23(1), 34–41. Uwanibe, J., Okorie, M., & Obi, A. (2022). Gender differences in superficial mycoses: A clinical epidemiology study. International Journal of Dermatology, 61(8), 967–973. Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., et al. (2016). Investigation of Candida auris transmission and persistence. Clinical Infectious Diseases, 64(2), 151– 157. Vijayalakshmi, K., Premalatha, B., & Ramanan, A. (2020). Impact of hyperglycaemia on host immunity and the risk of Candida infection. Journal of Diabetes Research, 2020, 6281743. Wajid, S. (2023). Diabetes mellitus and fungal infections: Epidemiology in tertiary care settings. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 17(5), 102700. Yadav, B., Prakash, A., & Jain, N. (2021). Emergence of Candida auris and antifungal resistance patterns: A global overview. Journal of Fungal Research and Practice, 7(1), 15–27.